Glycoprotein B / gB產(chǎn)品信息
英文名稱：Glycoprotein B of human cytomegalovirus
中文名稱：人巨細(xì)胞病毒包膜糖蛋白
靶點(diǎn)別稱：Glycoprotein B,gB,Envelope glycoprotein B
物種：HCMV/HSV-2
屬性：Protein
標(biāo)記：Unconjugated
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, 0.2 M Arginine, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Glycoprotein B / gB分子背景
Human cytomegalovirus is a species of the Cytomegalovirus genus of viruses, which in turn is a member of the viral family known as Herpesviridae or herpesviruses. It is typically abbreviated as HCMV or, commonly but more ambiguously, as CMV. CMV Virus Envelope Glycoportein B (CMV-GB) can be cleaved into glycoprotein GP55. Envelope glycoprotein that plays a role in host cell entry, cell to-cell virus transmission, and fusion of infected cells. CMV-GB may be involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. Furthermore, CMV-GB can interact with host integrin ITGB1, PDGFRA and EGFR that likely serve as postattachment entry receptors. Also, CMV-GB participates in the fusion of viral and cellular membranes leading to virus entry into the host cell. Membrane fusion is mediated by the fusion machinery composed at least of gB and the heterodimer gH/gL.
關(guān)鍵字： Glycoprotein B;Glycoprotein B蛋白;gB蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。